https://www.selleckchem.com/pr....oducts/pim447-lgh447
To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid arthritis (RA) despite ongoing treatment with methotrexate (MTX). This 52-week, multicentre, double-blind, placebo-controlled and active-controlled phase III trial evaluated once-daily oral filgotinib in patients with RA randomised 3323 to filgotinib 200 mg (FIL20 or filgotinib 100 mg (FIL10, subcutaneous adalimumab 40 mg biweekly, or placebo
Like
Comment
Share
